REFERENCES
- Boner G, Cooper ME. Diabetic nephropathy. Diabetes Technol Ther. 1999; 1: 489–496
- Cooper ME. Interaction of metabolic and hemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001; 44: 1957–1972
- Saxena U, Timmer RT, Pillarisetti S. New approaches for treatment of diabetic nephropathy: The endothelium as a target for drug discovery. Expert Opin Ther Targets. 2001; 5: 539–545
- Lundbaek K, Christensen NJ, Jensen VA, Johansen K, Olsen TS, Hansen AP, Orskov H, Osterby R. Diabetes, diabetic angiopathy, and growth hormone. Lancet. 1970; 2: 131–133
- Esposito C, Liu ZH, Striker GE, Phillips C, Chen NY, Chen WY, Kopchick JJ, Striker LJ. Inhibition of diabetic nephropathy by a GH antagonist: A molecular analysis. Kidney Int. 1996; 50: 506–514
- Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int Suppl. 1997; 60: 12–19
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656–660
- Masaoka T, Suzuki H, Hosoda H, Ota T, Minegishi Y, Nagata H, Kangawa K, Ishii H. Enhanced plasma ghrelin levels in rats with streptozotocin-induced diabetes. FEBS Lett. 2003; 541: 64–68
- Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002; 87: 2988–2991
- Mori K, Yoshimoto A, Takaya K, Hosoda K, Ariyasu H, Yahata K, Mukoyama M, Sugawara A, Hosoda H, Kojima M, Kangawa K, Nakao K. Kidney produces a novel acylated peptide, ghrelin. FEBS Lett. 2000; 486: 213–216
- Liu Y, Freedman BI. Genetics of progressive renal failure in diabetic kidney disease. Kidney Int Suppl. 2005; 99: 94–97
- Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia. 2000; 43: 1205–1223
- Segev Y, Eshet R, Rivkis I, Hayat C, Kachko L, Phillip M, Landau D. Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease. Nephrol Dial Transplant. 2004; 19: 3021–3028
- Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes. 1999; 48: 377–382
- Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol. 1999; 10: 2374–2381
- Yabuki A, Taharaguchi S, Ichii O, Kojima M, Nishi Y, Mifune H, Kamimura R, Matsumoto M, Suzuki S. Immunohistochemical localization of ghrelin in rodent kidneys. Histochem Cell Biol. 2006; 126: 231–238
- Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension. 2001; 37: 1053–1059
- Matsubara M. Renal sodium handling for body fluid maintenance and blood pressure regulation. Yakugaku Zasshi. 2004; 124: 301–309